South Staffordshire Joint FormularyCannock Chase Clinical Commissioning Group East Staffordshire Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group
Preservative-free (PF) formulations - Preservative intolerance should be diagnosed by an ophthalmologist. If PF formulation is warranted, proprietary preservative-free formulations (often available as unit dose preparations) should be prescribed if at all possible. Manufactured “specials” are unlicensed and almost invariably cost significantly more. PF formulations are appropriate, for example when a patient wears soft contact lenses or daily disposable contact lenses and wearing glasses instead is not a viable option such as for long courses OR where patient shows signs of preservative toxicity sometimes seen with multiple daily administrations.
Aciclovir 3% eye ointment
Urgently refer all patients with suspected herpes simplex to the hospital eye department
DISCONTINUED: GSK, the sole supplier of aciclovir eye ointment, plans to discontinue it from the worldwide market in 2018. Stock is anticipated to continue to be available in the UK until the end of June 2019, subject to demand.
An alternative agent is Ganciclovir 0.15% w/w eye gel (licensed for acute herpetic keratitis).
Non Formulary Items
Foscarnet intravitreal injection
Ganciclovir 0.15% ophthalmic gel (Virgan®)
Ganciclovir intravitreal injection
Trifluorothymidine eye drops
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.
Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.
Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)
Suitable first-line drugs for implementation in Primary Care